Design of Heart 2: A Phase 1b clinical trial of VERVE 102, an in vivo base editing medicine delivered by a GalNAc LNP and targeting PCSK9 to durably lower LDL cholesterol

Verve Therapeutics Inc. published this content on November 16, 2024, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 19, 2024 at 19:25 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]